/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

MINK THERAPEUTICS, INC.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$10.93 0.0196(1.96%) INKT at 04 Dec 2025 04:35 PM Biotechnology
Lowest Today 10.8435
Highest Today 10.905
Today’s Open 10.905
Prev. Close 10.72
52 Week High 76.00
52 Week Low 4.56
Day’s Range: Low 10.8435 High 10.905
52-Week Range: Low 4.56 High 76.00
1 day return -
1 Week return +4.07
1 month return -14.21
3 month return -17.87
6 month return +37.25
1 year return +1445.39
3 year return +334.85
5 year return -
10 year return -

Institutional Holdings

Vanguard Group Inc 0.53

Longbow Finance SA 0.37

Vanguard Total Stock Mkt Idx Inv 0.33

Geode Capital Management, LLC 0.25

Vanguard Institutional Extnd Mkt Idx Tr 0.22

BlackRock Inc 0.16

Fidelity Extended Market Index 0.12

Fidelity Nasdaq Composite Index 0.04

Fidelity Total Market Index 0.04

Fidelity Series Total Market Index 0.04

Spartan Extended Market Index Pool F 0.03

Wells Fargo & Co 0.02

Extended Equity Market Fund K 0.02

Northern Trust Extended Eq Market Idx 0.02

NT Ext Equity Mkt Idx Fd - L 0.02

Spartan Total Market Index Pool G 0.01

Bank of America Corp 0.01

Total Investment Management Inc 0.01

NT Ext Equity Mkt Idx Fd - NL 0.01

UBS Group AG 0.01

State St US Extended Mkt Indx NL Cl C 0.01

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.01

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

NT Ext Eq Mkt Indx Fd DC Lend T3 0.00

Covestor Ltd 0.00

BNYM Mellon SL Market Completion UC1 0.00

Advisor Group Holdings, Inc. 0.00

SSgA U.S. Total Market Index Strategy 0.00

Extended Equity Market Fund M 0.00

AVIP BlackRock Advtg Small Cp Gr Prtfl 0.00

BNP Paribas Arbitrage, SA 0.00

Morgan Stanley - Brokerage Accounts 0.00

Game Plan Financial Advisors, LLC 0.00

Northwestern Mutual Wealth Management Co 0.00

Hartland & Co 0.00

JPMorgan Chase & Co 0.00

KEY Financial, INC. 0.00

Hanson Mcclain Inc 0.00

JONES FINANCIAL COMPANIES LLLP 0.00

Tower Research Capital LLC 0.00

Market Status

Strong Buy: 2

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 50.98 M

PB Ratio 10.0516

PE Ratio 0.0

Enterprise Value 43.50 M

Total Assets 5.72 M

Volume 7778

Company Financials

Annual Revenue FY23:0 0.0M, FY22:2704743000 2704.7M, FY21:0 0.0M, FY20:0 0.0M, FY19:689626 0.7M

Annual Profit FY23:null 0.0M, FY22:-28244535000 -28244.5M, FY21:-28358591000 -28358.6M, FY20:null 0.0M, FY19:689626 0.7M

Annual Net worth FY23:-24769001 -24.8M, FY22:-24779823 -24.8M, FY21:-23114009 -23.1M, FY20:-15678517 -15.7M, FY19:-25914285 -25.9M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-43654 -0.0M, Q2/2025:-48763 -0.0M, Q1/2025:-50765 -0.1M, Q3/2024:-1884612000 -1884.6M, Q2/2024:-45100 -0.0M

Quarterly Net worth Q3/2025:-2887709 -2.9M, Q2/2025:-4237751 -4.2M, Q1/2025:-2766697 -2.8M, Q3/2024:-1806597 -1.8M, Q2/2024:-2701806 -2.7M

Fund house & investment objective

Company Information MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastro-esophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome. It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for auto-immune diseases. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; and ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Organisation Biotechnology

Employees 23

Industry Biotechnology

CEO Dr. Jennifer S. Buell Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow